C Diff Drug Development

A synthesized antibiotic derived from computer models of bacterial gene products appears to neutralize even drug-resistant bacteria. The compound, named cilagicin, works well in mice and employs a novel mechanism to attack MRSA, C. diff, and several other deadly pathogens.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Using neutrons, researchers at Oak Ridge National Laboratory pieced together the molecular mechanics behind a peptide’s ability to deal significant damage to

Exploring the benefits of metal Ions in phage cocktail for the treatment of methicillin-resistant Staphylococcus aureus infection

RBX2660 was shown to be safe and effective at reducing recurrence in #Cdiff #infection - great talk by Paul Feuerstadt at #DDW2022 #microbes #treatment pic.twitter.com/1bEk8bxH3S— Mindy Engevik (@MicroMindy) May 24, 2022

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to

Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial.  | Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. It hopes to present more data in May. The blueprint from the company comes after its shares have plummeted 50% in the last six months.

Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes pic.twitter.com/lBG1c3DsQu— Mindy Engevik (@MicroMindy) May 24, 2022

The detection of resistant strains of Clostridioides difficile against existing antibiotics and the side effects led to the investigation of alternative agents. Inhibition zones of various essential oils to four strains of C.difficile and other Clostridium species ranged from 8.32-44.18 mm. The high …

Since the advent of penicillin more than 90 years ago, antibiotic drugs have saved countless lives by preventing and treating bacterial infections. However, bacteria are rapidly developing new ways to ...

Adiso Therapeutics, Inc. announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product, for the prevention of C. difficile infection recurrence.

A pair of posters presented at Digestive Disease Week 2022 showed the efficacy of an investigational biotherapeutic in preventing Clostridioides difficile infection recurrence and restoring the microbiome.

Investigational microbiota-based live therapeutic RBX2660 was found to be safe and effective at reducing Clostridioides difficile (C difficile) recurrence, said Paul Feuerstadt, MD, assistant clinical professor at Yale University School of Medicine, gastroenterologist at PACT Gastroenterology Center, at Digestive Disease Week 2022.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

SAN DIEGO RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,&rdq

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

“@sanjiv_chopra ➡️Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff. Work in progress on alcoholism, autism, and others. ➡️AI will shape how we practice. EKG can predict cirrhosis ➡️CRISPR will shape the future of the human race @DDWMeeting #DDW2022”

Investigators sought information on how the infection is treated in outpatient clinics

“I'll be hosting this event next week - all my fellow #FMT nerds out there, please join me and @nadiamorim 💩🤓 #ECRchat @microbiome_net”

•Randomized, placebo-controlled trial•Standardized anaerobic feces storage •High alpha-diversity donors•Active UC frequently biologic-experienced recipients.•Study stopped early for futility #DDW2022— Kira Newman, MD, PhD (@KiraNewmanMDPhD) May 22, 2022

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes pic.twitter.com/mc7hGS0wLB— Mindy Engevik (@MicroMindy) May 21, 2022

Thomas Louie is showing beautiful work using 8 bacterial strains to prevent the recurrence of #Cdiff #DDW2022 #microbes pic.twitter.com/NOt5GtrsVI— Mindy Engevik (@MicroMindy) May 21, 2022

SER-109 for Recurrent Clostridioides difficile Infection. Reply

The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein …